BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Business

  Magellan Health Reports Fourth Quarter and Full Year 2018 Financial Results

  Magellan Health, Inc. announced financial results for the fourth quarter and full year ended December 31, 2018, as summarized below:

  February 28, 2019

   · 

  19 min read
• Drug Development

  Stero Biotechs to Commence Phase 2 Clinical Trial of ST-AH-01 Cannabidiol Formulation for Ground Breaking Maintenance Therapy and Steroid Reduction in Patients With Autoimmune Hepatitis

  Stero Biotechs has received Ethics Committee approval by Israel’s Ministry of Health and will soon enroll the first patients in a ground-breaking study to use CBD to reduce steroids in patients with liver disease.

  February 28, 2019

   · 

  3 min read
• Deals

  CytoSorbents to Report Fiscal 2018 Operating and Financial Results

  CytoSorbents Corporation, a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report fiscal 2018 financial results on Thursday, March 7, 2019 at 4:45PM EST.

  February 28, 2019

   · 

  4 min read
• Business

  Maze Therapeutics Launches with $191 Million to Focus on Translating Genetic Insights into New Medicines

  Third Rock Ventures announced the launch of Maze Therapeutics, a company focused on translating genetic insights into new medicines.

  February 28, 2019

   · 

  4 min read
• Business

  Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs

  Concert Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2018, as well as provided an update on its product pipeline and corporate activities.

  February 28, 2019

   · 

  13 min read
• Pharm Country

  Newron Supports Global Rare Disease Day® 2019

  Sponsoring international study to examine the burden of Rett syndrome on patients and caregivers, featured at Findacure’s Drug Repurposing for Rare Diseases Conference in the UK

  February 28, 2019

   · 

  9 min read
• Drug Development

  Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints

  Horizon Pharma plc announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease

  February 28, 2019

   · 

  10 min read
• Premier Health Announces Launch of Tech Enabled Mental Health Initiative

  Premier Health Group, a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce the launch of a technology enabled mental health initiative.

  February 28, 2019

   · 

  4 min read
• Policy

  BioVentrix Achieves 2019 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System

  BioVentrix, Inc., a pioneer of technologies and procedures for less invasive treatment of heart failure, announced a significant reimbursement achievement.

  February 28, 2019

   · 

  2 min read
• Business

  LEO Pharma Annual Results 2018: A Year in Line with Expectations

  LEO Pharma A/S announced its annual results for 2018 and outlined expectations for 2019.

  February 28, 2019

   · 

  1 min read